The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Recovery from deadly influenza infection may hinge on helping the lungs heal in addition to stopping the virus, according to ...

The field of traditional medicine, with its deep historical roots, offers a multitude of natural compounds with potential therapeutic benefits. Lately, ...

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Learn how long the flu lasts, what symptoms occur at every stage, and what you can do to feel better and lower the risk of ...

Despite a recent capital raise, Shelton-based antiviral drug developer NanoViricides Inc. disclosed it does not have enough cash to fund operations beyond mid-February and will need additional ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...

Scientists were pleased when they learned more about how the common cold gains a foothold in the body, identifying key cellular checkpoints that are important targets of the virus.